Market Intelligence, Clinical Progress, and High-Purity Reagents for Anticoagulant & Cytoprotective Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PROC (Protein C) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Zymogen) | PROC Recombinant Zymogen Protein (ECD-Fc / Mutant) High purity (>95%), Endotoxin <1EU/ug, Sequence Verified, HEK293 Expressed (Native Glycosylation & Gamma-Carboxylation) |
View PROC Products |
| Antigen (Active) | APC (Activated Protein C) Recombinant Enzyme Theoretical MW verified, Protease Activity Qualified by Chromogenic Substrate |
View PROC Products |
| Gene Delivery | PROC Lentivirus Particles / Promise-ORF Full-length ORF for stable cell line construction, Puromycin selection marker |
View PROC Products |
| Benchmark Ab | Anti-PROC Monoclonal Antibody (Clinical Biosimilar Sequence) Recombinant positive control for zymogen vs active form ELISA |
View PROC Products |
| Validator | PROC siRNA Set For knockdown verification in hepatocyte models |
View PROC Products |
| Related Target: PROS1 | Protein S (Cofactor) Essential for APC anticoagulant activity; required for Factor Va inactivation assays |
View PROS1 Products |
| Related Target: THBD | Thrombomodulin Forms complex with thrombin to activate PROC; upstream regulator |
View THBD Products |
| Related Target: PROCR | EPCR (Endothelial Protein C Receptor) Binding partner for APC cytoprotective signaling; counter-screening for specificity |
View PROCR Products |
| Related Target: F5 | Factor V APC substrate for anticoagulant activity; substrate cleavage assays |
View F5 Products |
Critical Assay Challenges & TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Zymogen vs Active Conformation Discrimination | Conformation-specific antibodies available; purified zymogen and pre-activated APC forms distinctly cataloged |
| Protease Activity Validation | Recombinant PROC proteins with preserved native folding and strict Sequence Verification |
| Cofactor Dependency Screening | High purity (>95%) PROS1 and THBD orthologs available without interfering contaminants |
| Species Cross-Reactivity (Cyno/Mouse/Human) | Human/Mouse/Cyno ortholog proteins available with >95% purity; Sequence alignment verified for epitope conservation |
| Vitamin K-Dependent Gamma-Carboxylation | HEK293 Expression System with gamma-carboxylase co-expression; Gla-domain functionality preserved |
| Substrate Specificity (Factor Va vs PAR1) | Recombinant F5 and PAR1 proteins available for selective cleavage assays |
| Lack of Reliable Controls | Clinical Benchmark Antibodies included for precise assay calibration |
| False Positives in Activity Assays | Validated PROC siRNA included for specificity checks; Protein S (PROS1) cofactor available for dependency validation |
Live PROC R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for Protein C (PROC) is evolving rapidly. Historically, broad systemic anticoagulation (e.g., drotrecogin alfa for sepsis) carried bleeding risks and was withdrawn. Modern R&D is shifting toward engineered cytoprotective variants, particularly Activated Protein C (APC) mutants that maximize anti-apoptotic and anti-inflammatory signaling through PAR-1 while minimizing anticoagulant activity. Key players include ZZ Biotech (3K3A-APC for ischemic stroke), Biogen, Lilly (legacy), Takeda (Ceprotin), and gene therapy leaders such as Spark Therapeutics and Novo Nordisk. Current R&D emphasizes subcutaneous delivery of zymogen forms for congenital Protein C deficiency, APC analogs with modified substrate selectivity, and AAV-mediated liver expression for durable correction. The convergence of rare disease gene therapy and engineered biologics is reshaping the competitive environment. PROC comprises multiple functional domains (Gla, EGF-like) that require proper post-translational modifications for activity; mutations in these regions are associated with PROC deficiency and thrombophilia (THPH3).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Engineered APC Variants | ZZ Biotech (3K3A-APC), Biogen, Lilly (Legacy) | Ischemic Stroke, Severe Sepsis (Re-evaluated), IBD | Substrate Selectivity Assay (Need mutant vs WT PROC proteins) |
| Recombinant Zymogen | Takeda, Plasma-Derivative Alternatives | Congenital Protein C Deficiency | Activation Kinetics (Need high-purity zymogen with correct Gla domain) |
| Gene Therapy (AAV-PROC) | Spark Therapeutics, Novo Nordisk, Various Biotechs | Inherited Protein C Deficiency | Expression Validation (Need lentivirus for in vitro POC) |
| Monoclonal Antibodies | Preclinical phase | Sepsis / Coagulopathy | Epitope Mapping (Need accurate Sequence Verified antigens) |
| Small Molecule Activators | Early Biotech | Thrombosis Prevention | Zymogen Activation Assay (Need conformationally intact PROC) |
Key Assay Recommendations for Molecular Differentiation
Developing a best-in-class PROC/APC therapy requires balancing safety (bleeding risk) and efficacy (cytoprotection). Recommended assays include: chromogenic substrate assays for protease activity, clotting time tests (APTT/PT) with PROS1 cofactor, endothelial cell barrier protection assays using EPCR-expressing cells, and substrate selectivity assays comparing cleavage of Factor Va vs PAR1. TarMart provides matched reagents for each step, including wild-type and mutant proteins, lentiviral constructs, validated siRNAs, and benchmark antibodies.